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A B S T R A C T
The PowerPlex1 Fusion 6C System is a 27-locus, six-dye, multiplex that includes all markers in the
expanded CODIS core loci and increases overlap with STR database standards throughout the world.
Additionally, it contains two, rapidly mutating, Y-STRs and is capable of both casework and database
workﬂows, including direct ampliﬁcation. A multi-laboratory developmental validation study was
performed on the PowerPlex1 Fusion 6C System. Here, we report the results of that study which followed
SWGDAM guidelines and includes data for: species speciﬁcity, sensitivity, stability, precision,
reproducibility and repeatability, case-type samples, concordance, stutter, DNA mixtures, and PCR-
based procedures. Where appropriate we report data from both extracted DNA samples and direct
ampliﬁcation samples from various substrates and collection devices. Samples from all studies were
separated on both Applied Biosystems 3500 series and 6-dye capable 3130 series Genetic Analyzers and
data is reported for each. Together, the data validate the design and demonstrate the performance of the
PowerPlex1 Fusion 6C System.
ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
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The PowerPlex1 Fusion 6C System is a 27-locus, six-dye,
multiplex (Fig. 1) that allows co-ampliﬁcation and ﬂuorescent
detection of the 20 autosomal loci in the expanded CODIS core loci
[1] (CSF1PO, FGA, TH01, TPOX, vWA, D1S1656, D2S1338, D2S441,
D3S1358, D5S818, D7S820, D8S1179, D10S1248, D12S391, D13S317,
D16S539, D18S51, D19S433, D21S11 and D22S1045) as well as
Amelogenin and DYS391 for gender determination. The Penta D,
Penta E and SE33 loci are also included to increase discrimination
and allow searching of databases that include proﬁles with these* Corresponding author.
E-mail address: martin.ensenberger@promega.com (M.G. Ensenberger).
http://dx.doi.org/10.1016/j.fsigen.2015.12.011
1872-4973/ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
nd/4.0/).loci. Finally, two rapidly mutating Y-STR loci, DYS570 and DYS576,
are included in the multiplex.
A multi-laboratory evaluation of the PowerPlex1 Fusion 6C
System was performed following SWGDAM guidelines [2]. The
eight sites that completed testing are: The Connecticut Depart-
ment of Emergency Services and Public Protection, DNA Unit; Erie
County Central Police Services Forensic Laboratory; Los Angeles
County Sheriff's Department Crime Laboratory; Minnesota Bureau
of Criminal Apprehension; National Institute of Standards and
Technology (NIST), Applied Genetics Group; National Institute of
Toxicology and Forensic Science, Madrid, Spain; North Dakota
Ofﬁce of Attorney General, Crime Laboratory Division; and
Promega Corporation. The combined results of these laboratories
are presented here to demonstrate the capabilities and limitations
of the PowerPlex1 Fusion 6C System.article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. PowerPlex1 Fusion 6C System ampliﬁcation of 1 ng 2800M DNA. 2800M DNA was ampliﬁed using PowerPlex1 Fusion 6C following the recommended protocol.
Ampliﬁed product was separated on an Applied Biosystems 3500 Genetic Analyzer. Panel labeled “ . . . ” is Amelogenin. Scale is 10000RFU.
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2.1. DNA
For most studies presented here, human DNA was puriﬁed from
non-cell line sources by organic extraction or using DNA IQTM
Casework Pro Kit for Maxwell1 16 (Promega, Madison, WI). Once
puriﬁed, DNA samples were quantiﬁed by the PowerQuantTM
System (Promega). For the mixture study, human DNA sources
were combined at their prescribed ratios based on their
concentration. Non-human DNA was from a collection previously
described [3]. Additional sources of DNA were purchased from
ATCC (Manassas, VA), Coriell Institute for Medical Research
(Camden, NJ), Zyagen (San Diego, CA), and EMD Millipore (Billerica,
MA). Two of the collaborating laboratories also tested non-human
DNA samples from their own collections.
2.2. Direct ampliﬁcation substrates
Volunteers created samples from buccal cells using EasiCollect
devices (GE Healthcare Life Sciences, Piscataway, NJ), Buccal DNA
CollectorTM devices (Bode Cellmark Forensics, Lorton, VA),
OmniSwabs (GE Healthcare Life Sciences), or cotton swabs (Puritan
Medical Products, Guilford, ME). Blood samples were created by
spotting whole blood, collected in BD vacutainers anti-coagulated
with K2EDTA (Becton Dickinson, Franklin Lakes, NJ), on What-
manTM FTA1 classic cards (GE Healthcare, Life Sciences) or
WhatmanTM Protein Saver 903 cards (GE Healthcare, Life Sciences).
Informed consent was obtained from all volunteers prior to
collecting their samples for experimentation purposes.2.3. DNA ampliﬁcation
DNA ampliﬁcation was performed using an Applied Biosystems
(Foster City, CA) GeneAmp1 PCR System 9700 or Veriti1 Thermal
Cycler following the ampliﬁcation cycling parameters described in
the PowerPlex1 Fusion 6C System technical manual [4]. Ampliﬁ-
cation reactions generally contained 1.0 ng DNA in 25 mL and used
29-cycles as described in the technical manual. Direct ampliﬁca-
tion reactions generally used 12.5 mL reaction volumes and
25 cycles also as described in the technical manual. Unless noted
otherwise, direct ampliﬁcation reactions were performed using
one-1.2 mm disk punched from paper storage devices or 2 mL of a
buccal swab extract generated with SwabSolutionTM Reagent
(Promega). NonFTA card punches were pre-treated with Punch-
SolutionTM Reagent (Promega) prior to ampliﬁcation. All FTA1 and
nonFTA card punches in a reaction volume of 12.5 mL or less
included AmpSolutionTM Reagent (Promega) in the reaction mix as
described in the technical manual. For the reaction mix component
titration studies, each component was altered as indicated, while
the other components remained constant. Unless noted otherwise,
protocols in the PowerPlex1 Fusion 6C System technical manual
were followed. All data described in this manuscript were
generated with components from the commercial release of the
PowerPlex1 Fusion 6C System.
2.4. Data analysis
The PowerPlex1 Fusion 6C System is a six-dye chemistry.
Spectral resolution was established using the PowerPlex1 6C
Matrix Standard [5] to allow evaluation of each ﬂuorescent dye
Table 1
Summary of microorganisms tested as a part of the species speciﬁcity of the
PowerPlex1 Fusion 6C System. Each DNA sample was ampliﬁed using the listed
amount of DNA following the standard ampliﬁcation protocol for extracted DNA
(29-cycles). Samples were detected with an Applied Biosystems 3500 or 3500xL
Genetic Analyzer using a 1.2 kV 15 s or 1.2 kV 24 s injection, respectively.
Microorganism DNA Amount tested Peak over 175RFU
Acinetobacter calcoaceticus 10 ng No
Acinetobacter lwofﬁi 10 ng No
Alcaligenes faecalis 10 ng No
Bordetella parapertussis 10 ng No
Bordetella pertussis 10 ng No
Candida albicans 10 ng No
Citrobacter freundii 10 ng No
Enterococcus faecalis 10 ng No
Escherichia coli 10 ng No
Flavobacterium odoratum 10 ng No
Fusobacterium nucleatum 10 ng No
Haemophilus inﬂuenza 6 ng No
Lactobacillus acidophilus 10 ng No
Micrococcus luteus 10 ng No
Morganella morganii 10 ng No
Neisseria lactamica 10 ng No
Neisseria meningitides 6 ng No
Proteus mirabilis 10 ng No
Providencia stuartii 10 ng No
Pseudomonas aeruginosa 10 ng No
Pseudomonas stutzeri 10 ng No
Saccharomyces cerevisiae 10 ng No
Salmonella enteritidis 10 ng No
Serratia marcescens 10 ng No
Shigella ﬂexneri 10 ng No
Staphylococcus aureus 6 ng No
Staphylococcus epidermidis 10 ng No
Streptococcus agalactiae 6 ng No
Streptococcus mitis 10 ng No
Streptococcus mutans 10 ng No
Streptococcus pneumonia 6 ng No
Streptococcus salivarius 10 ng No
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Standard 500 and allelic ladder mix provided with the PowerPlex1
Fusion 6C System. Separation of ampliﬁed products was performed
on the Applied Biosystems 3500 (1.2 kV, 15 s injections), 3500xL
(1.2 kV, 24 s injections), 3130 (3.0 kV, 3 s injections), or 3130xl
(3.0 kV, 5 s injections) Genetic Analyzers (note that 3130 and
3130xl instruments were upgraded to be 6-dye capable). All
instruments used a 36 cm capillary array and POP41 polymer from
Applied Biosystems. For all experiments 1 mL of ampliﬁed sample
or ladder was added to a mixture containing 9.5 mL deionized
formamide and 0.5 mL WEN ILS-500. Generally, samples were
denatured for 3 min at 95 C followed by snap cooling on ice (note
that one laboratory snap cooled using a frozen aluminum block,
one laboratory did not snap cool after denaturation, and one
laboratory did not heat denature or snap cool). Initial fragment
sizing and allele calling was performed using GeneMapper1 ID-X
v.1.4 (Applied Biosystems) with a 175RFU calling threshold (3500,
3500xL data) or with a 50RFU calling threshold (3130, 3130xl data).
2.5. Stutter calculation
Six hundred and ﬁfty two human DNA samples were ampliﬁed
using the recommended ampliﬁcation protocol and analyzed on
the Applied Biosystems 3500xL Genetic Analyzer. Stutter peaks
were determined as three bases smaller (n-3) than D22S1045, four
bases smaller (n-4) than tetranucleotide repeats, and ﬁve bases
smaller (n-5) than pentanucleotide repeats (0.5 bases). Stutter in
the plus position for all loci was also calculated from the data set.
Where applicable (D1S1656, D19S433, SE33, FGA), n-2 stutter was
also measured. For all stutter measurements a high level of
stringency was imposed to collect accurate stutter data. Stutter
peaks at the repeat position between heterozygous alleles two
repeat units apart were not included to eliminate the additive
effect of plus and minus stutter from the two peaks. Stutter was not
calculated unless the true allele peak heights were at least 500RFU
and did not exceed 15000RFU. Stutter percentages were calculated
by dividing the peak height of the stutter peak by the peak height of
the true allele.
2.6. Inhibitor stock sample preparation
Hematin (Sigma, H3281) (Sigma–Aldrich, St. Louis, MO) was
dissolved in 1N sodium hydroxide at a concentration of 40 mM and
then diluted to 2 mM in water. Humic acid (Sigma, 53680) was
dissolved in water at a concentration of 5 mg/mL. Tannic acid
(Sigma, 403040) was dissolved in water at a concentration of 5 mg/
mL. EDTA (Sigma, ED2SS) was originally dissolved at a concentra-
tion of 0.5 M, pH 8.0 and then diluted to 2 mM in water. All inhibitor
stocks were diluted to their working concentrations in water.
2.7. Concordance study
DNA samples used for the concordance study were created as
previously described [6]. Brieﬂy, anonymous liquid blood samples
with self-identiﬁed ethnicities were purchased from Interstate
Blood Bank (Memphis, TN) and Millennium Biotech, Inc. (Ft.
Lauderdale, FL). The blood samples were extracted, quantiﬁed, and
previously typed with Identiﬁler1 (Applied Biosystems),
NGMSElect1 (Applied Biosystems), PowerPlex1 16 (Promega),
PowerPlex1 ESX 17 and ESI 17 (Promega), PowerPlex1 Fusion
(Promega), PowerPlex1 Y23 (Promega), and Investigator 24plex QS
(Qiagen, Hilden, Germany). The six genomic components of
Standard Reference Material1 (SRM) 2391c PCR-based DNA
Proﬁling Standard were also evaluated for concordance to certiﬁed
materials. A total of 658 samples were evaluated in this study for
concordance testing. All genotyping was performed at NIST withGeneMapper1 ID-X v1.4 software (Applied Biosystems) using
manufacturer provided allelic ladders, bins, and panels.
3. Results and discussion
3.1. Species speciﬁcity
The primers included in the PowerPlex1 Fusion 6C System have
been designed to amplify human DNA. Despite that, it is possible
for some primers to recognize sites within other non-human
sources of DNA. DNA samples encountered in laboratories may
contain trace or even excess non-human DNA. Potential sources of
this extraneous DNA are: the source of the DNA (e.g., microbes in
saliva or buccal samples), the environment from which it was
collected, and contamination of laboratory reagents or tubes.
Contamination can be an issue for both puriﬁed DNA and direct
ampliﬁcation samples. Three laboratories contributed data from
non-human DNA samples. The scope of this study was expanded
from previous developmental validation studies [7,8]. In total,
55 unique non-human DNA samples were tested with some
overlap between the test sites. All DNA samples were ampliﬁed
using the recommended protocol and separated on a 3500 series
Genetic Analyzer. A threshold of 175RFU was used to determine the
presence of artifact peaks. Two laboratories contributed 32 unique
microbial sources of DNA to the study. Table 1 summarizes the
testing set-up and results for each of the microbe DNAs tested.
Despite being run at an amount much higher than what is
recommended for extracted DNA, none of the microbes tested
yielded any peaks above the 175RFU threshold. Of the 32 sources of
DNA, two samples (Escherichia coli and Pseudomonas aeruginosa)
were tested at both sites. Each of the microorganisms tested at
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injection) and yielded no peaks above 50RFU.
Two laboratories contributed 19 unique non-primate vertebrate
sources of DNA to the study. Table 2 summarizes the testing set-up
and results for each of the non-primate vertebrate DNAs tested.
Five non-primate vertebrate DNA sources (cat, chicken, dog, rabbit,
rat) were tested at both sites and similar results were obtained for
each. One site tested both male and female sources for cat and dog.
A representative electropherogram for each DNA source which
yielded a peak above the 175RFU threshold is included in
Supplemental Fig. 1. The ﬁndings for non-primate vertebrate
DNA sources are also summarized in Table 3. Each of the
vertebrates tested at Promega were also run on a 3130 Genetic
Analyzer (3 kV 3 s injection, 50RFU threshold) and yielded similar
results.
Two laboratories contributed four unique primate sources of
DNA to the study. Table 4 summarizes the testing set-up and
results for each of the primate DNAs tested. A representative
electropherogram for each 1 ng sample of primate DNA source is
included in Supplemental Fig.1. As seen with previous studies [7,8],
primate sources of DNA yield many peaks throughout the proﬁle.
Primate DNA results are distinguishable from human DNA results
by their number of off-ladder peaks and the irregular, and often
imbalanced nature, of ampliﬁcation across the multiplex.
3.2. Sensitivity
Seven laboratories contributed to the sensitivity study using
extracted DNA. Laboratories were provided with two unique stock
solutions of human male DNA. These stock solutions were diluted
serially to create two sets of samples used to amplify DNA ranging
in amounts from 2 ng to 31.25 pg. Each amount of both DNAs were
ampliﬁed in 25 mL reaction volumes (according to the recom-
mended protocol) in replicates of four. Among the test sites a total
of seven 3500 series Genetic Analyzers and two 3130 series Genetic
Analyzers were used for the separation and detection of the
ampliﬁed product. For allele designation and peak height ratio
determination a 175RFU threshold was used for data fromTable 2
Summary of non-primate vertebrates tested as a part of the species speciﬁcity of the
PowerPlex1 Fusion 6C System. Each DNA sample was ampliﬁed using the listed
amount of DNA following the standard ampliﬁcation protocol for extracted DNA
(29-cycles). Samples were detected with an Applied Biosystems 3500xL Genetic
Analyzer using a 1.2 kV 24 s injection.
Non-primate vertebrate DNA Amount tested Peak over 175RFU
Cat (female) 10 ng No
Cat (male) 10 ng No
Chicken 10 ng Yes
Chipmunk 10 ng Yes
Cow 10 ng Yes
Deer 10 ng No
Dog (female) 10 ng No
Dog (male) 10 ng No
Duck 10 ng Yes
Ferret 10 ng No
Goat 10 ng Yes
Horse 10 ng No
Iguana 10 ng No
Mouse 10 ng Yes
Opossum 10 ng Yes
Pig 10 ng Yes
Rabbit 10 ng No
Rat 10 ng Noa
Sheep 10 ng Yes
Turtle 10 ng Yes
Woodchuck 10 ng No
a An artifact in the FL-channel at 300 bases is listed in the PowerPlex1 Fusion 6C
System Technical Manual; each test site also produced this peak, but it was not
above the 175-RFU threshold.3500 Genetic Analyzers and a 50RFU threshold for data from
3130 Genetic Analyzers. Loci with homozygous peaks and Y-STR’s
were excluded from peak height ratio calculations; Amelogenin
was included. When drop out occurred, those loci were also
excluded from peak height ratio calculations. Data from all sites
and instrumentation are summarized in Fig. 2.
On both 3500 and 3130 Genetic Analyzers 100% of alleles were
called at amounts as low as 250 pg. On 3500 Genetic Analyzers at
125 pg, 99.7% of alleles (2653/2660) were called. At 62.5 pg and
31.25 pg 82% and 44% of alleles, respectively, were called. On 3130
Genetic Analyzers at 125 pg, 99.7% of alleles (758/760) were called.
At 62.5 pg and 31.25 pg 84% and 58% of alleles, respectively, were
called. The loci which exhibited drop out did not show a
discernable pattern and appeared to be caused by stochastic
levels of DNA. Average peak height ratios when amplifying 1 ng of
DNA on both 3500 and 3130 Genetic Analyzers was 89%. On the
3130 Genetic Analyzer, saturation was common in 2 ng samples
which could impact the peak height ratio results; the 3500 data did
not show the same level of saturation with 2 ng samples.
We also examined the sensitivity of the PowerPlex1 Fusion 6C
System using direct ampliﬁcation samples. For this study one, two,
or three FTA1 punches (1.2 mm) were ampliﬁed in 12.5 mL reaction
volumes set up according to recommendations. Two laboratories
contributed data for this experiment. Laboratories were provided
with blood and buccal samples on FTA1 cards from three donors.
Each lab produced results on both a 3500 and 3130 Genetic
Analyzer (3130 data not shown). Supplemental Fig. 2 summarizes
data from both sites. For buccal samples,100% of alleles were called
at each number of punches tested (1144/1144 for 1 X and 3 X
punches 1096/1096 [one failed sample was omitted] for 2 X
punches). For blood samples, 100% of alleles (1096/1096) were
called using one punch. At two punches, 99.8% (1094/1096) of
alleles were called. When three punches are added, inhibitors
present in the samples begin to overwhelm the ampliﬁcation
chemistry and 77% (840/1096) of alleles were called.
3.3. Stability
Four laboratories examined the ability of the PowerPlex1
Fusion 6C System to obtain results from DNAs subjected to
environmental and chemical insults. Each lab was provided with
inhibitor stocks as well as DNA stocks. From each stock, dilutions
were made to achieve the desired experimental design. Inhibitors
tested were hematin (500 mM, 750 mM, 1000 mM), humic acid
(100 ng/mL, 200 ng/mL, 300 ng/mL), tannic acid (500 ng/mL, 750 ng/
mL, 1000 ng/mL), and EDTA (750 mM, 1000 mM, 1250 mM). Results
from the study can be found in Supplemental Fig. 3. Each inhibitor
concentration was tested with two male DNA sources in replicates
of four. Ampliﬁcation reactions were set up in 25 mL reaction
volumes following the recommended protocol.
The PowerPlex1 Fusion 6C System performs very similarly to
the PowerPlex1 Fusion System in the presence of the inhibitors
tested [7]. With hematin, full proﬁles were generated in the
presence of 500 mM with 14% of alleles still present at 1000 mM.
For humic acid, full proﬁles were generated in the presence of
100 ng/mL with 24% of alleles still present at 300 ng/mL. An average
of 90% of alleles were called at 500 ng/mL tannic acid with 54% of
alleles still called at 1000 ng/mL. When testing EDTA, we found that
99% of alleles were called at 750 mM and 10% of alleles remained at
1250 mM. Only slight variation was seen between the test sites for
most inhibitors tested. One site had less success with tannic acid
which led to an increase in variability for that data set. The
concentration ranges we tested were selected to be where we
would expect impact to be seen on ampliﬁcation reactions. Thus,
small variation in the creation and use of test stocks for each
inhibitor can lead to subtly noticeable differences in the data.
Table 3
Summary of non-primate vertebrate DNA reactivity with the PowerPlex1 Fusion 6C System.
DNA source Artifact size(s) Allele call
Chicken 221 bp (JOE), 300 bp (TMR) OMR, 12.3 in D7S820
Chipmunk 163 bp (FL), 72 bp (JOE), 88 bp (TMR) OL in D1S1656, OMR, 8 in TH01
Cow 98 bp (FL) OL in D3S1358
Duck 94 bp (FL) OL in D3S1358
Goat 484 bp (FL) OMR
Mouse 347 bp (JOE) 12 in CSF1PO
Opossum 198 bp (CXR), 203 bp (CXR) 6.2 in D19S433, OL in D19S433
Pig 259–260 bp (FL), 368–372 bp (JOE), 369–370 bp (CXR) OL and 9 in D10S1248, OMR, 28 in SE33
Sheep 477 bp (FL) OL in Penta E
Turtle 122 bp (FL) OL in D3S1358
Table 4
Summary of primates tested as a part of the species speciﬁcity of the PowerPlex1
Fusion 6C System. Each DNA was ampliﬁed at the listed concentration using the
standard ampliﬁcation protocol for extracted DNA (29-cycles). Samples were
detected using an Applied Biosystems 3500xL Genetic Analyzer using a 1.2 kV 24 s
injection.
Primate DNA Amount tested Peak over 175RFU
Chimpanzee (male) 1 ng Yes
Gorilla 1 ng Yes
Macaque 1 ng Yes
Orangutan 1 ng Yes
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Sizing precision is critical for accurate genotyping. Therefore,
migration and sizing precision must be consistent and within the
bin window to ensure proper allele designation. Precision of the
PowerPlex1 Fusion 6C System was evaluated on 3500, 3500xL,
3130, and 3130xl Genetic Analyzers. For each instrument two full
injections (3130xl data had two ladder replicates that were omitted
due to injection issues) containing PowerPlex1 Fusion 6C System
allelic ladder were run and sized with the supplied internal lane
standard (WEN ILS-500). Data analysis was done using Gen-
eMapper1 ID-X using the local Southern method. For each allele,
sizes were averaged and a standard deviation was calculated from
the replicate ampliﬁcation reactions (Supplemental Figs. 4–7). As
expected, the largest allele sizes yield the greatest standard
deviation. For the 3500 and 3500xL Genetic Analyzers, the
maximum standard deviation of an allele was less than 0.07 bases.
For the 3130 and 3130xl Genetic Analyzers, the maximum standard
deviation of an allele was less than 0.1 bases. These results show
that the precision throughout the assay is adequate to size and
distinguish alleles which differ by as little as one base.
3.5. Reproducibility and repeatability
A DNA sample ampliﬁed with an STR system should yield the
same result across sites, operators, and instruments. To demon-
strate that proﬁles obtained with the PowerPlex1 Fusion 6C
System are reproducible and suitable for comparison across
different laboratories, six test sites genotyped SRM2391c (National
Institute of Standards and Technology, Gaithersburg, MD). Each
laboratory extracted the DNA from Component E and Component F
and quantiﬁed all six components using their established methods
and protocols. Each component of SRM 2391c was then ampliﬁed
at a concentration of 1 ng. Each site generated genotypes that were
fully concordant with their certiﬁed values [9] (data not shown).
Each lab also received 2800M control DNA along with two to three
(depending on the experiments conducted) puriﬁed DNA samples
and/or samples on FTA1, nonFTA, cotton swab, and buccal swab. Inevery experiment from every laboratory, all sources of DNA
produced a genotype concordant with known values.
3.6. Case-type samples
The ability to obtain reliable results from samples typically
encountered as casework in the laboratory was assessed by four
test sites. Mixtures, low template amount, degradation, and
inhibition can all impact results and interpretation of data from
case-type samples. A total of 147 non-probative samples were
ampliﬁed and analyzed in this study (Table 5). The samples tested
as a part of this study represented the typical variation in DNA
source, quality, and quantity encountered with case-type samples.
One site had previously tested some of their samples with another
chemistry; those results are summarized in Table 6. Almost all of
the samples tested that had been previously genotyped with
Identiﬁler1 yielded more alleles with PowerPlex1 Fusion 6C. This
is not surprising given the increased number of loci in the
PowerPlex1 Fusion 6C multiplex. The three samples (swab of car
door handle, swab of cell phone, and swab of cash register) which
yielded fewer alleles with PowerPlex1 Fusion 6C were all mixed
proﬁles with low peak heights. While peaks were detected with
Identiﬁler1 on a 3130 using a 50RFU threshold, many peaks fell
below the 175RFU threshold of the 3500 used to detect Power-
Plex1 Fusion 6C ampliﬁcations. The time the samples had been in
storage between ampliﬁcations might have also contributed to the
decreased number of alleles seen with PowerPlex1 Fusion 6C with
these samples. Where there was overlap between loci, all
previously genotyped samples gave concordant allele calls with
PowerPlex1 Fusion 6C. Degraded samples generally had dropout
beginning at a very similar size as seen in previously generated
data (not shown). One test site reported two samples from saliva
stains which showed inhibition when previously genotyped;
additionally, when quantiﬁed by qPCR (Quantiﬁler1 Duo DNA
Quantiﬁcation Kit, Applied Biosystems) these samples reported no
DNA and their IPCs indicated inhibition. When these samples were
genotyped with the PowerPlex1 Fusion 6C System, they produced
45 and 42 alleles, respectively (Supplemental Figs. 8 and 9). The
alleles spanned the entire assay and included the largest loci in
each dye. As expected, touch samples produced lower peak heights
and genotypes from multiple contributors. One example of the
results from a complex mixture ampliﬁed with the PowerPlex1
Fusion 6C System is shown in Supplemental Fig. 10. Epithelial
fractions from differential extractions that showed male DNA
carryover were detected in Amelogenin and the three Y-STRs in
PowerPlex1 Fusion 6C System ampliﬁcations (Supplemental
Fig. 11).
3.7. Characterization of genetic markers and concordance
Allele frequencies [6,10–13], Y-haplotype [14–16], and physical
mapping [17,18] have been well characterized and are available for
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Fig. 2. Sensitivity using extracted DNA. Ampliﬁcation reactions containing 2 ng, 1 ng, 500 pg, 250 pg, 125 pg, 62.5 pg, and 31.25 pg of DNA were performed on four replicates of
two human DNA sources using the PowerPlex1 Fusion 6C system following the recommended protocol. Data in panel A are results from 3500 series Genetic Analyzers. Data in
panel B are results from 3130 series Genetic Analyzers. A 175RFU and 50RFU threshold were used on 3500 series and 3130 series Genetic Analyzers, respectively. The
percentage of alleles called (black) and peak height ratio (gray) are shown. Error bars show the standard deviation between all replicates.
Table 5
Case-type samples evaluated with the PowerPlex1 Fusion 6C System. Four sites
evaluated 147 non-probative samples from their own collections.
Sample type Sample number Sites
Envelope 5 1
Cigarette butt 13 2
Hair 12 2
Tissue (biological) 3 1
Differential extraction (sperm and epithelial fractions) 18 2
Blood stain 11 2
Saliva stain 2 1
Gun swab 9 1
Touch sample 49 3
Buccal swab 5 1
Blood card 3 1
Tooth 4 1
Bone 6 1
Muscle 1 1
Saliva 3 1
Liver 1 1
Kidney 1 1
Heart 1 1
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demonstrate concordance, NIST genotyped DNA samples from
652 unrelated individuals with the PowerPlex1 Fusion 6C System.
Results from this study were compared with genotypes generatedpreviously with other STR systems. Out of 33,558 alleles compared,
two discordant calls were observed resulting in a 99.994%
concordance between the PowerPlex1 Fusion 6C System and
the NIST data set. One discordant sample generated a Y, Y genotype
at Amelogenin with the PowerPlex1 Fusion 6C System and all
other systems with the exception of Investigator1 ESSplex,
Investigator1 ESSplex SE Plus, Investigator1 IDplex, and Inves-
tigator1 Hexaplex ESS which produced an X, Y genotype. The
second discordant sample generated an 8, 9.3 genotype at
D7S820 with PowerPlex1 Fusion 6C as well as Identiﬁler1
whereas PowerPlex1 16, AmpFLSTR1 MiniFilerTM, and Inves-
tigator1 IDplex produced an 8, 11 genotype. Sequencing revealed
the cause of this discrepancy to be a ﬁve base deletion in the
PowerPlex1 Fusion 6C System amplicon that is outside the primers
used in some other STR chemistries.
3.8. Stutter
When STR sequences are ampliﬁed by PCR, slippage events are
known to occur [19,20]. The artifacts that result from these
slippage events are known as stutter. They are most notably found
one repeat unit shorter than an allele peak. They can also be seen
two repeat units below and one repeat unit above an allele. Called
stutter peaks can confound STR results; consideration of stutter
peaks is a part of the interpretation of most samples. Stutter peak
analysis was conducted using the NIST population dataset for the
Table 6
Comparison of case-type samples previously genotyped with Identiﬁler1. One test site provided results from samples previously tested with Identiﬁler1 or Identiﬁler1 Plus.
For each sample, the total number of alleles called with each kit are shown. Identiﬁler1 and Identiﬁler1 Plus ampliﬁcation products were separated and detected using a
3130 Genetic Analyzer with a 50RFU threshold used for analysis. Ampliﬁcation products from the PowerPlex1 Fusion 6C System were separated and detected using a
3500 Genetic Analyzer with a 175RFU threshold used for analysis. PowerPlex1 Fusion 6C System ampliﬁcations targeted 1.0 ng of DNA (or maximum input volume (15 mL)
when that was not possible) using the recommended protocol. Where loci had overlap between kits, they were examined for concordance.
Sample Type Identiﬁler1 Allele # Fusion 6C Allele # Concordance of alleles
Envelope 27 32 Yes
Cigarette butt 28 46 Yes
Cigarette butt 28 47 Yes
Cigarette butt 32 45 Yes
Cigarette butt 29 38 Yes
Cigarette butt 30 46 Yes
Cigarette butt 30 28 Yes
Cigarette butt 30 48 Yes
Hair 18 20 Yes
Hair 0 0 N/A
Hair 0 0 N/A
Hair 0 11 N/A
Hair 12 37 Yes
Hair 11 39 Yes
Tissue 31 48 Yes
Cigarette butt 8 7 Yes
Blood stain 27 40 Yes
Blood stain (ﬂoor) 28 47 Yes
Blood stain (parking brake) 27 44 Yes
Blood stain (glass) 32 50 Yes
Blood stain (window ledge) 27 27 Yes
Swab of crowbar 29 44 Yes
Swab of beer bottle 0 0 N/A
Swab of car door handle 22 (mixture) 7 Yes
Swab of cell phone 25 (mixture) 8 Yes
Swab of cash register 14 (mixture) 2 Yes
Buccal swab 27 45 Yes
Buccal swab 30 49 Yes
Buccal swab 31 46 Yes
Blood sample 29 47 Yes
Blood sample 26 40 Yes
Blood stain 32 50 Yes
Table 7
PowerPlex1 Fusion 6C System stutter summary.
Minus stutter Plus stutter n-2 stutter
n Average (%) SD n Average (%) SD n Average (%) SD
D3S1358 563 9 1.5 534 0.8 0.3
D1S1656 800 8.5 2 757 1.1 0.4 909 2 0.5
D2S441 677 4.8 1.4 595 0.8 0.3
D10S1248 440 8 1.7 115 0.4 0.3
D13S317 501 4.9 1.8 495 0.8 0.5
Penta E 827 2.7 1.5 216 0.5 0.5
D16S539 631 6.4 1.8 444 1.1 0.6
D18S51 762 8.1 2.2 549 1 0.6
D2S1338 839 8.5 1.7 103 0.6 0.5
CSF1PO 456 5.5 1.9 487 1.1 0.9
Penta D 520 1.9 0.9 122 1.1 0.9
TH01 700 2.2 0.9 143 0.5 0.3
vWA 536 6.9 2.5 394 0.8 0.6
D21S11 734 8.2 1.5 753 1.2 0.5
D7S820 522 4.7 1.6 473 0.7 0.4
D5S818 451 6.1 1.6 502 1 0.4
TPOX 623 2.5 1 75 0.3 0.3
D8S1179 713 7.3 1.5 422 1 0.8
D12S391 777 9.1 2.8 216 0.8 0.6
D19S433 599 7 1.7 145 0.9 0.6 220 0.5 0.3
SE33 971 10 2 600 1 0.8 1069 4.9 0.6
D22S1045 581 7.2 3.2 713 4.4 1.5
DYS391 588 6.7 0.9 307 0.7 0.4
FGA 704 7.1 1.8 539 1 0.6 381 0.5 0.2
DYS576 589 8.5 1.4 426 1.3 0.7
DYS570 581 8.9 1.4 451 1 0.5
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stutter analysis can be found in Table 7. The table summarizes the
minus and plus stutter for each locus in the multiplex. For each
type of stutter at each locus, the number of stutter peaks counted
(n) along with the average stutter percentage and standard
deviation (SD) are shown. Some loci (D1S1656, D19S433, SE33, and
FGA) have n-2 peaks associated with them as well. The default
locus-speciﬁc stutter ﬁlter values included in the stutter ﬁles are
the average stutter plus three standard deviations.
3.9. Mixture study
Three test sites evaluated the ability to resolve minor
contributor alleles with the PowerPlex1 Fusion 6C System. Each
site was provided with 11 mixture samples at differing ratios of
male:female (M:F) DNA (1:0, 19:1, 9:1, 5:1, 2:1, 1:1, 1:2, 1:5, 1:9,
1:19 and 0:1). Each lab set up each mixture ratio in replicates of
four. A summary of all data generated can be seen in Fig. 3. On
average (M:F and F:M) we were able to identify 100% (828/828) of
the unique minor contributor alleles at a 1:2 ratio, 99% (821/828) at
a 1:5 ratio, 96% (798/828) at a 1:9 ratio, and 74% (613/828) at a
1:19 ratio. Interestingly, in this study when males were the minor
contributor, we successfully genotyped greater numbers of unique
minor contributor alleles. Much of the difference was due to
successful allele calling at the three Y-STR markers included in the
PowerPlex1 Fusion 6C System. One test site also ran their
ampliﬁcation reactions on a 3130 Genetic Analyzer using a 3 kV,
3 s injection at a 50RFU threshold and produced comparable
results (100%, 99%, 96%, and 78% of unique minor contributor
alleles called at 1:2, 1:5, 1:9, and 1:19 ratios, respectively) (data not
shown).
3.10. PCR-based procedures—cycle number
When amplifying extracted DNA, the recommended protocol
for the PowerPlex1 Fusion 6C System includes 29-cycles. For direct
ampliﬁcation protocols it is recommended that laboratories
optimize their cycle number (23–27-cycles) for each sample type.
Four test sites examined the effect of differing cycle numbers on
extracted DNA (Supplemental Fig. 12). Each site tested two DNA
sources in replicates of four. Each DNA was ampliﬁed using 1 ng
and 200 pg per reaction. At 1 ng 100% of alleles were successfully
called at all cycles tested. At 200 pg, 98% (1491/1520), 99.9% (1470/
1471) and 99.9% (1519/1520) of alleles were called at 28-, 29-, and
30-cycles, respectively. Fewer total alleles were examined at 29-
cycles due to one injection failure. Three out of the four sites called0
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Fig. 3. Mixture analysis. A two-source DNA mixture was created at various ratios (1 ng tot
protocol. Ampliﬁcation reactions were performed according to the recommended proto
Analyzers. A 175RFU threshold was used for analysis. The average percentage of the mino
deviation of replicate results from all sites.100% of alleles of 200 pg samples at 29- and 30-cycles. Two out of
the four sites called 100% of alleles of 200 pg samples at all cycle
numbers. One test site also ran their ampliﬁcation reactions on a
3130 Genetic Analyzer using a 3 kV, 3 s injection and 50RFU
threshold. All alleles were called at both concentrations across all
cycle numbers tested.
Two sites also tested differing cycle numbers (24-cycles, 25-
cycles, 26-cycles) with various direct ampliﬁcation substrates
(blood on FTA1, buccal on FTA1, blood on 903, Bode buccal DNA
collectorsTM, cotton swabs, and OmniSwabs). Each site tested three
donors in replicates of four from each sample type. Ampliﬁcation
was performed using the protocols recommended in the technical
manual for a reaction volume of 12.5 mL. The results of direct
ampliﬁcation (Supplemental Fig. 13) show more variability than
was seen with extracted DNA. This is not surprising given the
potential for variation in donor cell count, collection technique,
and differences in cell density from punch-to-punch (especially
with buccal samples on cards). 100% of alleles were called when
amplifying cotton swab extracts, OmniSwab extracts, Bode Buccal
DNA CollectorsTM and blood on FTA1 at all cycle numbers tested.
Blood on 903 yielded 94% (986/1051), 100% (1096/1096), and 98%
(1069/1088) of alleles at 24-, 25-, and 26-cycles, respectively.
Buccal on FTA1yielded 89% (1020/1144), 95% (1092/1144), and 98%
(1118/1144) of alleles at 24-, 25-, and 26-cycles, respectively.
Punch-to-punch variability was the main sources of variability
seen in this experiment. One test site also ran their direct
ampliﬁcation reactions on a 3130 Genetic Analyzer using a 3 kV,
3second injection and 50RFU threshold. All alleles were called for
all substrates across all cycle numbers tested.
3.11. PCR-based procedures—annealing temperature
The optimized annealing temperature for the PowerPlex1
Fusion 6C System is 60 C. This annealing temperature was selected
after extensive stressing of the multiplex during development
(data not shown) and changing the annealing temperature is not
recommended. However, it is possible for slight temperature
variations to exist between thermal cyclers. Here, we examined the
effect of intentionally increased and decreased annealing temper-
atures. Three sites evaluated the performance of the PowerPlex1
Fusion 6C System at annealing temperatures that included 58 C
and 62 C. Each test site used two DNA sources in replicates of four.
Each DNA was ampliﬁed using 1 ng and 200 pg per reaction. The
results of the annealing temperature study can be found in
Supplemental Fig. 14. At 1 ng 100% of alleles were successfully
called across all annealing temperatures. At 200 pg, 100% 1:2  M:F 1:5 M:F 1:9 M:F 1:19 M:F
al DNA) and ampliﬁed with the PowerPlex1 Fusion 6C System using the recommend
col. Ampliﬁcation products were separated and detected using 3500 series Genetic
r alleles detected at a given mixture ratio is shown. Error bars represent the standard
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called at 58 C, 60 C, and 62 C annealing temperature, respective-
ly. Fewer total alleles were examined at 62 C due to the omission
of data from one failed sample. Representative electropherograms
illustrating the effects at each annealing temperature can be seen
in Fig. 4. Overall peak height decreased as annealing temperature
increased. Loci that were most affected by increased annealing
temperature were Amelogenin, Penta E, D16S539, D2S1338, and
the loci in the TOM channel (DYS391, FGA, DYS576, and DYS570). At
reduced annealing temperature, one DNA produced an artifact in
the TMR channel at around 169 bases. This artifact was not present
in the other test DNA or 2800M control DNA at 58 C, so it might
have been a DNA-speciﬁc artifact. One test site also ran their
ampliﬁcation reactions on a 3130 Genetic Analyzer using a 3 kV,
3second injection and 50RFU threshold. All alleles were called at all
concentrations across all annealing temperatures tested. These
results indicate the robustness of the PowerPlex1 Fusion 6C
System to withstand unintentional temperature variations.
Two sites also tested differing annealing temperatures with
direct ampliﬁcation of blood and buccal samples on FTA1 cards
(Supplemental Fig. 15). Each site was provided with and tested
three donor samples in replicates of four from both sample types.
Ampliﬁcation was performed using the recommended protocols
found in the technical manual including a reaction volume of
12.5 mL. On average, the two sites successfully genotyped 100%
(1096/1096) of the alleles from the blood on FTA1 punches at 58 C
and 60 C. At 62 C, the sites genotyped 94% (1035/1096) of alleles
called. We saw greater variability from site-to-site with the buccal
on FTA1 samples. Site one successfully genotyped 100% of the
alleles at 58 C and 60 C as well as 98% of the alleles at 62 C. Site
two was only able to genotype 84% (483/572), 88% (463/524), and
67% (385/572) of the alleles from all donors of buccal on FTA1 at
58 C, 60 C, and 62 C, respectively. Samples with drop-out from
site two generally had the appearance of control ampliﬁcation
reactions with no punch. The ampliﬁcation plates were checked to
ensure all wells did contain a punch. However, it is still possible
that while punches made it into all wells, some might not have
settled into the reaction mix prior to ampliﬁcation. Punches were
only taken from white regions on the indicating FTA1 paper used
for all buccal on FTA1 samples, however, white areas are only
indicative of previous wetness, not the presence of buccal cells.
These results underscore the variability inherent in directFig. 4. Representative electropherograms of human genomic DNA at 1 nampliﬁcation, especially buccal on storage cards. One test site
(site one) also ran their direct ampliﬁcation reactions on a
3130 Genetic Analyzer using a 3 kV, 3 s injection and 50RFU
threshold. For buccal on FTA1 samples, all alleles were called for all
donors across all annealing temperatures tested. For blood on
FTA1 samples,100% of alleles were called for all donors at 58 C and
60 C. At 62 C, 99% (542/548) of alleles were called for all donors.
3.12. PCR based procedures—reaction volume
The recommended reaction volume of the PowerPlex1 Fusion
6C System is 25 mL for extracted DNA and 12.5 mL for direct
ampliﬁcation (a 25 mL protocol is also included as an appendix to
the technical manual) [4]. Reaction volumes of 25 mL, 12.5 mL, and
6.25 mL were tested in this experiment. Decreased reaction volume
may be a useful adaptation when a minimal DNA template volume
is available since a reduction in reaction volume effectively
increases the template concentration within the reaction. Howev-
er, increased stochastic effects as well as a concomitant increase in
the concentration of any inhibitors or contaminating DNA will also
occur and should be considered. Three sites tested reaction volume
with extracted DNA and three sites tested reaction volume with
direct ampliﬁcation. Test sites received DNA or direct ampliﬁcation
substrates to use with this experiment. Extracted DNA from two
donors was tested at concentrations of 40 pg/mL (1 ng in 25 mL) and
8 pg/mL (200 pg in 25 mL) in replicates of four at each reaction
volume (30-cycles). Blood and buccal on FTA1 samples from three
donors were tested in replicates of four at each reaction volume
(25-cycles). Results of the reaction volume study are summarized
in Supplemental Fig. 16. Across all sites and reaction volumes
tested extracted DNA at 40 pg/mL successfully genotyped all alleles
with the PowerPlex1 Fusion 6C System. All alleles were called from
extracted DNA at 8 pg/mL at 25 mL and 12.5 mL reaction volumes. At
6.25 mL with extracted DNA at 8 pg/mL (50 pg total DNA), 98%
(1571/1597) of alleles were called. Blood on FTA1 samples
produced full genotypes at 25 mL and 12.5 mL reaction volumes.
At a reaction volume of 6.25 mL, blood on FTA1 sample
ampliﬁcation reactions began to show inhibition and resulted in
an average of 96% (1583/1644) of alleles called. Buccal on FTA1
samples again showed the most variability (punch-to-punch) with
the following results: 95% (1631/1716) at 25 mL, 99.4% (1705/1716)
at 12.5 mL, and 94% (1613/1716) at 6.25 mL.g subjected to differing annealing temperatures. Scale is 25000RFU.
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The concentrations of primers included in the 5X Primer Pair
Mix were optimized throughout development to ensure ampliﬁ-
cation efﬁciency across all loci. Deliberate changes of the ﬁnal
primer concentration within a reaction mix should not be made.
Final primer concentrations of 0.75X, 0.9X, 1.0X, 1.1X, and 1.25X
were examined (with 1 ng DNA) for their impact on the Power-
Plex1 Fusion 6C System ampliﬁcation reactions. Final primer
concentrations of 0.75X, 1.0X and 1.25X were also examined with
200 pg DNA. One site tested two extracted DNA sources in
replicates of four on the 3500 and 3130 Genetic Analyzers and
found no instances of drop-out for any alleles when testing any
primer pair concentration with either 1 ng or 200 pg DNA samples.
Generally, increasing the primer pair concentration led to an
increase in overall peak height. The overall average peak height
(1 ng ampliﬁcation reactions) doubled when increasing from 0.75X
primer pair (5900RFU) to 1.25X primer pair (12,500RFU) on the
3500 Genetic Analyzer (data not shown). No new artifacts were
observed with the different primer pair concentrations. All of the
no template controls and the 2800M positive controls performed
as expected across all concentrations of primer mix tested. The
ability of the PowerPlex1 Fusion 6C System to yield reliable results
across such a deliberately large change in total primer concentra-
tion, suggests its robustness when confronted with the more likely
smaller inadvertent changes (i.e., pipetting error and incomplete
mixing).
Primer Pair concentration was also tested with direct ampliﬁ-
cation of blood and buccal samples on FTA1 cards. For each primer
pair concentration (0.75X, 0.9X, 1.0X, 1.1X, and 1.25X), two donors
in replicates of four from both sample types were tested.
Ampliﬁcation was performed using the recommended protocols
found in the technical manual including a reaction volume of
12.5 mL. Ampliﬁcation reactions were run on both the 3500 and
3130 Genetic Analyzers. On the 3500 Genetic Analyzer (175RFU
threshold), all alleles were called across all primer pair concen-
trations with all replicates of both sample types. When the
ampliﬁcation plate was run on the 3130 Genetic Analyzer
(Supplemental Fig. 17), all alleles were called for each condition
with the exception of buccal on FTA1 ampliﬁed with 1.25X primer
pair which called 99.7% (383/384) of the possible alleles.
3.14. PCR-based procedures—master mix, magnesium, polymerase
concentration
The ﬁnal concentration of the PowerPlex1 Fusion 6C System 5X
Master Mix, along with magnesium and polymerase, were
optimized during development to ensure robust performance
and minimal artifacts. In this experiment, each was tested at 0.75X,
0.9X, 1.0X, 1.1X, and 1.25X concentrations in reaction mixes set up
to amplify 1 ng of extracted DNA as well as blood and buccal on
FTA1 samples. Each was also tested at 0.75X, 1.0X, and 1.25X
concentrations in reaction mixes set up to amply 200 pg of
extracted DNA. Supplemental Fig. 18 summarizes the results across
the titrations with 1 ng extracted DNA samples. Neither peak
height nor within-dye balance is impacted much by the titration of
the polymerase used in the PowerPlex1 Fusion 6C System 5X
Master Mix. When the concentration of magnesium was increased,
the JOE (green) and TOM (purple) dye channels showed the largest
increase in average peak height. TMR (yellow) and CXR (red)
showed the least response to increasing magnesium concentra-
tions. The most reactive loci were Amelogenin, D1S1656, D16S539,
D18S51, FGA, DYS576, and DYS570. The least reactive loci were
D2S441, Penta E, vWA, TPOX, D8S1179, SE33, and D22S1045.
Changes in concentration of the Master Mix elicited the most
dramatic effects on peak height. The JOE and TOM dye channelswere again the most responsive to increases in Master Mix
concentration. The TMR and CXR dye channels were again the least
responsive. Peak heights rose signiﬁcantly between 0.75X and 0.9X
Master Mix concentrations before leveling off through the
remainder of the titration. For all titrations of all components,
we observed no drop-out for any of the replicates of either DNA at
200 pg. We did, however, observe increased n + 1 activity at
D1S1656 at the highest concentrations of Master Mix in
ampliﬁcation reactions of 200 pg DNA samples. Together, the data
demonstrate that the design of the provided Master Mix is well-
optimized for the provided Primer Pair Mix and recommended
reaction conditions.
Direct ampliﬁcation substrates (blood and buccal on FTA1)
were also tested in reactions containing varying amounts of Master
Mix, magnesium, and polymerase (Supplemental Fig. 19). For this
experiment both substrates were tested using two donors in
replicates of four. Punches from blood on FTA1 samples
successfully genotyped 100% of alleles for all donors and replicates
across all concentrations of Master Mix, polymerase, and magne-
sium. Punches from buccal on FTA1 samples genotyped 100% of
alleles from all conditions with three exceptions: 0.9X Master Mix
yielded 98% (328/334) of alleles, 0.75X magnesium yielded 99.7%
(371/372) of alleles, and 1.0X magnesium yielded 98% (365/372) of
alleles. Here again, the allelic drop-out seen with buccal on FTA1
samples were due to punch-to-punch variability inherent in the
sample type.
4. Conclusions
The PowerPlex1 Fusion 6C System was developed for STR
genotyping and human identiﬁcation. This study examined the
performance of the PowerPlex1 Fusion 6C System by thorough
examination of parameters established by its design and protocol
(component concentrations, reaction volume, ampliﬁcation con-
ditions, reaction volume, sensitivity, cross reactivity with non-
human species, stutter, and precision). We also examined factors
related to implementation and use of the PowerPlex1 Fusion 6C
System (instrumentation, case-type samples, mixture samples,
reproducibility, concordance, stability, sample quantity, and
sample quality). Experiments were conducted with both extracted
DNA and cells (blood and buccal) collected on substrates for direct
ampliﬁcation. Eight sites participated in this developmental
validation study following SWGDAM guidelines. The results of
the study documented here demonstrate the reliability of results
from the PowerPlex1 Fusion 6C System and provide context for
internal validation studies [2,21] that each laboratory should
complete using the sample types, procedures, and instrumentation
that comprise their workﬂow.
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